Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.

@article{Ford2007ResultsOT,
  title={Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.},
  author={Judith M. Ford and Wendy F. Seiferheld and Jeffrey R. Alger and Genevieve N. Wu and Thyra J Endicott and Minesh Mehta and Walter P. Curran and S C Phan},
  journal={International journal of radiation oncology, biology, physics},
  year={2007},
  volume={69 3},
  pages={831-8}
}
PURPOSE Motexafin gadolinium (MGd) is a putative radiation enhancer initially evaluated in patients with brain metastases. This Phase I trial studied the safety and tolerability of a 2-6-week course (10-22 doses) of MGd with radiotherapy for glioblastoma multiforme. METHODS AND MATERIALS A total of 33 glioblastoma multiforme patients received one of seven MGd regimens starting at 10 doses of 4 mg/kg/d MGd and escalating to 22 doses of 5.3 mg/kg/d MGd (5 or 10 daily doses then three times per… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Tissue and plasma thioredoxin reductase expressions in patients with glioblastoma multiforme.

Journal of neurological surgery. Part A, Central European neurosurgery • 2013

Potential usefulness of radiosensitizers in glioblastoma.

Neurosurgery clinics of North America • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…